Pharmatrophix

The company shares news and media about company milestones and scientific updates.

Anne Chun Longo is Co-Founder of PharmatrophiX and served as its Founding CEO from 2006 to 2025. She is now Senior Advisor, continuing to advance the company’s work to develop therapeutics for neurodegenerative diseases.

David Setboun, Pharm.D., MBA, is a life sciences CEO with more than 20 years of experience in biotech and pharmaceutical organizations across neurology, rare disease, oncology, and aging science. He has held senior leadership roles at Eli Lilly, AstraZeneca, and Biogen.

Dr. Reiman is Executive Director of the Banner Alzheimer’s Institute, Chief Executive Officer of Banner Research, and Professor of Psychiatry at the University of Arizona.

Dr. Longo is Chairman of the Board and Co-founder of PharmatrophiX. He received an MD and a PhD in Neurosciences from UC San Diego and completed neurology training at UC San Francisco, where he became an assistant professor and was promoted to professor.

PharmatrophiX develops small-molecule drugs for neurodegeneration.

The page provides contact details for reaching PharmatrophiX about media, academic research, and investor relations.

Alzheimer's and Neurodegenerative diseases damage brain connections. PharmatrophiX developing drug targets synaptic resilience.

Safeguarding user information requires strict privacy controls. PharmatrophiX protects personal data and user confidentiality.

The page outlines the legal terms and conditions governing the PharmatrophiX website, along with user guidelines and corporate policies.